|
|
Research to Reality:
Human-Centered Approaches to Recruitment and Retention
|
Jun. 28, 2021, 12 - 1 p.m
The goal of this series is to provide an understanding of the ethical background, regulatory knowledge, and models of best practices for conducting research when the participants represent special populations and vulnerable subjects. More Details
|
Now Accepting Applications
Application Closes: Sep. 6, 2021
The overarching goal of the BU CTSI Pilot Grant Program is to help investigators explore and solve major challenges in translational science, especially those that address the special health problems of our urban communities, by developing and deploying new tools, methods, and processes to expedite clinical and translational research and discovery.
|
|
|
 |
New Funding Opportunities |
|
|
|
|
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)
National Heart, Lung, and Blood Institute (NHLBI)
|
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)
Surgical Disparities Research (R01 - Clinical Trial Optional)
National Institute on Minority Health and Health Disparities (NIMHD)
|
|
|
|
Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)
Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Clinical Trial Not Allowed)
Notice of Special Interest (NOSI): Administrative Supplements to support engagement of functionally diverse teams to advance ongoing NIDA-funded research
National Institute on Drug Abuse (NIDA)
|
|
|
|
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional)
National Institute of Mental Health (NIMH)
|
Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)
Fogarty International Center (FIC)
|
NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
|
|
|
|
|
Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 2021
LOI is due: Jun. 1, 2021
Full applications are due: Aug. 31, 2021
PCORI seeks to fund projects that address methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. Read More
|
|
|
|
|
Airway-on-a-chip Screens Drugs for Use Against COVID-19
To screen drugs against viruses like SARS-CoV-2, researchers often use human cell lines grown in the lab. These are easy to work with and relatively inexpensive. Read More
|
|
|
|
|
A New Data Map Will Help Track Systemic Health Disparities Across the Country
The data map is capable of tracking multiple conditions and determinants that have impacted COVID-19 outcomes and exacerbated health inequities. Read More
|
|
|
|
|
A DNA COVID-19 Vaccine, Delivered With Help of an Electrical Pulse, Shows Early Promise
DNA vaccines have only been approved for veterinary use so far, as their immune responses in humans are often not enough to offer clinically meaningful protection. Read More
|
|
|
|
|
Studies Confirm COVID-19 mRNA Vaccines Safe, Effective for Pregnant Women
After vaccination, women in all groups produced antibodies against SARS-CoV-2. Importantly, those antibodies neutralized SARS-CoV-2 variants of concern. Also, those antibodies were found in infant cord blood and breast milk, suggesting that they were passed on to afford some protection to infants early in life. Read More
|
|
|
|
|
4th Annual Children's National - NIAID Symposium (Virtual)
Jun. 3 - 4, 2021, 12 - 2:30 p.m.
This virtual event highlights current research on COVID-19 and multisystem inflammatory syndrome in children (MIS-C), and the intersectionality of COVID-19, allergy, and immunology on the pediatric population.
|
|
|
|
|
Summit on Anti-SARS-CoV-2 Antibodies for Treatment and Prevention of COVID-19
Jun. 15, 2021, 11 a.m.
Lessons learned on clinically relevant anti-SARS-CoV-2 antibodies for the treatment and/or prevention of COVID-19 and to identify key unanswered scientific questions to catalyze antibody clinical development and implementation. Read More
|
|
|
|
|
Diverse Voices: COVID-19, Intersectionality, and the Health of Women
Jun. 24, 2021, 1 p.m.
ORWH will host “Analysis and Action: Applications of Intersectionality in COVID-19,” the second webinar in the “Diverse Voices: COVID-19, Intersectionality, and the Health of Women” speaker series. Read More
|
|
|
|
|
The Funding Acknowledgement |
|
|
|
|
The Funding Acknowledgement guides recipients of BU CTSI services, resources, or funding for projects or research through the grant citation process. All recipients are required to cite our grant number in associated presentations and journal publications.
|
|
|
|
|
|
|
|
|
